Trademark Search in Canada

TILZELIOS

View On IC.GC.CA

REGISTERED

on 5 Jul 2023

Last Applicant/ Owned by

Iovance Biotherapeutics GmbH

c/o Bratschi AG,Zweigniederlassung Zug,Gubelstrasse 11CH-6300 Zug

Serial Number

2071627 filed on 21^st Oct 2020

Registration Number

TMA1188225 registered on 5^th Jul 2023

Registration expiry Date

21^st Oct 2030

Correspondent Address

SMART & BIGGAR LP

Scotia Plaza, 40 King Street West40th FloorToronto

ONTARIO

M5H3Y2

TILZELIOS

Trademark usage description

pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutic Read More

Classification Information

Class [005]
Pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutical preparations and biological preparations for the treatment of cancer, immune system related and oncological diseases and disorders; pharmaceutical products and biological preparations for medical diagnostics in the fields of cancer, oncology, and immune system diseases and disorders.

Classification kind code

Class [044]
Medical services, namely, cell modification for treatment of cancer, oncological diseases and disorders, immune system diseases and disorders; immunotherapy treatments; medical diagnosis and treatment services, namely, medical analysis services for cancer diagnosis and prognosis, medical analysis services for the diagnosis and prognosis of oncological and immune system diseases and disorders, medical diagnosis and treatment services in the fields of cancer, oncology and immune system diseases and disorders; provision of information on oncology and immunotherapy treatments; providing medical information and consultancy services relating to diagnosis and treatment for cancer, oncological diseases and disorders, and immune system diseases and disorders, and relating to immunotherapy treatments, tumor infiltrating lymphocyte (TIL) therapies, T-cell-based immunotherapy and peripheral blood lymphocyte (PBL) therapies; providing pharmaceutical information; providing medical information in the field of isolation, collection, and banking of human biological tissue for immunotherapy; collection and preservation of biological tissues for diagnostic or treatment purposes in the fields of cancer, oncology and immune system diseases and disorders.

Classification kind code

Mark Details

Serial Number

2071627

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 20^th Jun 2022	Agent Changed
Submitted for opposition 22 on 8^th Apr 2022	Search Recorded
Submitted for opposition 20 on 8^th Apr 2022	Examiner's First Report
Submitted for opposition 223 on 8^th Apr 2022	Total Provisional Refusal
Submitted for opposition 256 on 18^th Oct 2021	Notification of Possible Opposition Sent
Submitted for opposition 257 on 17^th Dec 2020	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 16^th Dec 2020	Formalized
Submitted for opposition 1 on 16^th Dec 2020	Created
Submitted for opposition 30 on 21^st Oct 2020	Filed
Submitted for opposition 228 on 21^st Oct 2020	International Registration

Manage cookies

You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously

Analytics

Analytical cookies are used to understand how visitors interact with the website.

Functional

Functional cookies help perform certain functionalities like collecting feedback, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website.